United Therapeutics
UTHR
356 hedge funds and large institutions have $6.54B invested in United Therapeutics in 2020 Q4 according to their latest regulatory filings, with 68 funds opening new positions, 101 increasing their positions, 140 reducing their positions, and 42 closing their positions.
169% more call options, than puts
Call options by funds: $39.7M | Put options by funds: $14.7M
63% more funds holding in top 10
Funds holding in top 10: 8 → 13 (+5)
62% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 42
53% more capital invested
Capital invested by funds: $4.26B → $6.54B (+$2.28B)
7% more funds holding
Funds holding: 332 → 356 (+24)
1.97% more ownership
Funds ownership: 95.03% → 97% (+2%)
28% less repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 140
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$374M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$69.4M |
| 3 |
EP
Eversept Partners
New York
|
+$28.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$27.7M |
| 5 |
SCM
Scopia Capital Management
New York
|
+$27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$64.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$45.9M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$41.8M |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$34.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$32.2M |
UTHR Hedge Fund Activity: Q4 2020 in Review
356 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q4 2020, worth a combined $6.54B — up 53% from $4.26B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new UTHR positions and 42 closed out — a net gain of 26 holders — while 101 added to existing stakes and 140 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $374M. The largest seller was Great Point Partners, cutting an estimated $64.4M.
- 356 institutional investors held United Therapeutics (UTHR) as of Q4 2020, up from 332 in Q3 2020.
- Funds reported $6.54B of United Therapeutics stock for Q4 2020, up 53% quarter-over-quarter.
- 68 funds opened new United Therapeutics positions in Q4 2020 and 42 closed out, a net change of +26 holders.
- The largest United Therapeutics buyer in Q4 2020 was Avoro Capital Advisors, an estimated $374M added.
- The largest United Therapeutics seller in Q4 2020 was Great Point Partners, an estimated $64.4M sold.
Based on aggregated 13F filings for Q4 2020.